94 related articles for article (PubMed ID: 18843884)
1. Biological basis for a proper clinical application of alpha interferons.
Antonelli G
New Microbiol; 2008 Jul; 31(3):305-18. PubMed ID: 18843884
[TBL] [Abstract][Full Text] [Related]
2. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
[TBL] [Abstract][Full Text] [Related]
3. Biologic activities of natural and synthetic type I interferons.
Pfeffer LM
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-63-S9-69. PubMed ID: 9208874
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C.
Scagnolari C; Antonelli G
Expert Opin Biol Ther; 2013 May; 13(5):693-711. PubMed ID: 23350850
[TBL] [Abstract][Full Text] [Related]
5. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
[TBL] [Abstract][Full Text] [Related]
6. New developments in interferon therapy.
Tossing G
Eur J Med Res; 2001 Feb; 6(2):47-65. PubMed ID: 11313191
[TBL] [Abstract][Full Text] [Related]
7. Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases.
Brideau-Andersen AD; Huang X; Sun SC; Chen TT; Stark D; Sas IJ; Zadik L; Dawes GN; Guptill DR; McCord R; Govindarajan S; Roy A; Yang S; Gao J; Chen YH; Skartved NJ; Pedersen AK; Lin D; Locher CP; Rebbapragada I; Jensen AD; Bass SH; Nissen TL; Viswanathan S; Foster GR; Symons JA; Patten PA
Proc Natl Acad Sci U S A; 2007 May; 104(20):8269-74. PubMed ID: 17494769
[TBL] [Abstract][Full Text] [Related]
8. Differential expression and activity of the porcine type I interferon family.
Sang Y; Rowland RR; Hesse RA; Blecha F
Physiol Genomics; 2010 Jul; 42(2):248-58. PubMed ID: 20406849
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of antiviral activity between FeIFN-omega and FeIFN-alpha].
Wang H; Jia X; Yang L; Sun L; Wang H; Liu W
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1556-60. PubMed ID: 19160837
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions.
Yanai Y; Sanou O; Kayano T; Ariyasu H; Yamamoto K; Yamauchi H; Ikegami H; Kurimoto M
J Interferon Cytokine Res; 2001 Oct; 21(10):835-41. PubMed ID: 11710996
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA.
Atreya PL; Kulkarni S
Virology; 1999 Sep; 261(2):227-41. PubMed ID: 10497108
[TBL] [Abstract][Full Text] [Related]
12. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host.
Braun M; Vierling JM
Liver Transpl; 2003 Nov; 9(11):S79-89. PubMed ID: 14586901
[TBL] [Abstract][Full Text] [Related]
13. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls.
Castelruiz Y; Larrea E; Boya P; Civeira MP; Prieto J
Hepatology; 1999 Jun; 29(6):1900-4. PubMed ID: 10347136
[TBL] [Abstract][Full Text] [Related]
14. Biological characterization of three novel variants of IFN-alpha 13 produced by human placental trophoblast.
Fink T; Zachar V; Ebbesen P
Placenta; 2001; 22(8-9):673-80. PubMed ID: 11597187
[TBL] [Abstract][Full Text] [Related]
15. Dose-Dependent Differences in HIV Inhibition by Different Interferon Alpha Subtypes While Having Overall Similar Biologic Effects.
Schlaepfer E; Fahrny A; Gruenbach M; Kuster SP; Simon V; Schreiber G; Speck RF
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760614
[TBL] [Abstract][Full Text] [Related]
16. [Anti-viral proteins: from interferon alpha to its receptor].
Chieux V; Hober D; Chehadeh W; Wattr P
Ann Biol Clin (Paris); 1999 May; 57(3):283-90. PubMed ID: 10377478
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.
Buckwold VE; Wei J; Huang Z; Huang C; Nalca A; Wells J; Russell J; Collins B; Ptak R; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
Antiviral Res; 2007 Feb; 73(2):118-25. PubMed ID: 16987555
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of interferon mediated anti-viral resistance.
Clarke CJ; Trapani JA; Johnstone RW
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):117-30. PubMed ID: 12476793
[TBL] [Abstract][Full Text] [Related]
19. Biological characterisation of a recombinant Atlantic salmon type I interferon synthesized in Escherichia coli.
Ooi EL; Verjan N; Hirono I; Nochi T; Kondo H; Aoki T; Kiyono H; Yuki Y
Fish Shellfish Immunol; 2008 May; 24(5):506-13. PubMed ID: 18329900
[TBL] [Abstract][Full Text] [Related]
20. Effect of alpha-interferons on immune function.
Herberman RB
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-78-S9-80. PubMed ID: 9208876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
